À propos de CARE™
Le Comité académique de CARE™ célèbrera sa 15e année en 2020 et entend poursuivre le débat en cours sur les biosimilaires et l’accès à l’innovation à l’aide d’un programme robuste en 2020 et au-delà.
Nous élaborons des initiatives de formation destinées à nos pairs, aux infirmières, aux pharmaciens, aux patients, au gouvernement ainsi qu’aux payeurs du secteur privé.
SAVOIR PLUS
Événements actuels
Publications [récentes]
CARE™ at ASH happened on December 6th, 2019. It is the largest gathering of hematologists outside of Canada. CARE™ has provided a summary report and the speaker slides presentations.
Voir la publication
Hematology
CARE™ at ASH 2019:
Presentations & Report
Rheumatology
CARE™ Perspectives:
More Innovation Needed in Rheumatology
Select members of the CARE™ Rheumatology Faculty used the 2019 ACR conference as an opportunity to meet and discuss the impact of, and continued support for access to innovation and biosimilar adoption, specifically from a Canadian context/perspective.
Voir la publication
The CARE™ ACG/UEGW 2019 Conference Report highlights key news in gastroenterology with a specific focus on inflammatory bowel disease (IBD), framed from a Canadian perspective.
Voir la publication
Gastroenterology
CARE™ Perspectives:
ACG/UEGW 2019
Genitourinary
CARE™ Perspectives:
ESMO 2019
2018 and 2019 have seen numerous data updates and news that could affect the management of prostate cancer (PC) in Canada. The following CARE™ Conference Report from ESMO 2019 focuses on prostate cancer updates.
Voir la publication
Publications actuels
#DDW Report is online! Covering news and developments in UC and CD informed abstracts from #DDW2020. Dr. John Marshall, CARE™ Faculty reviews treatment options and considers impact within the context of Canadian #healthcare https://careeducation.ca/reports/care-perspectives-ddw-report/ @marshllj
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30848-5/fulltext#.XvOq3pN50CM.twitter
